Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Estrella Immunopharma Inc ESLA
$0.71
▼ -0.89%
($-0.01)
⬇️ Below Yest. Low
Open
$0.71
Prev Close
$0.72
Day Range
$0.71 – $0.77
52W Range
$0.69 – $3.15
Market Cap
$30.71M
Beta
0.91
EPS (TTM)
$-0.35
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-07-19 |
| Shares Out. | 43,030,000 |
| Website | estrellabio.com/ ↗ |
| Phone | 15103189098 |
| Net Income | -$2.3M |
| Total Assets | $3.7M |
| Total Liabilities | $8.9M |
| Equity | -$5.3M |
About Estrella Immunopharma Inc
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
Estrella Immunopharma Inc is a publicly traded company under the ticker symbol ESLA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)
📰 Latest News for ESLA
Estrella Immunopharma Activates Second Clinical Facility For Its Current STARLIGHT-1 Phase I/II Clinical Study Of EB103 In Participants With Relapsed Or Refractory B-Cell Non-Hodgkin’s Lymphoma
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
Estrella Immunopharma Doses First Participant In Its Current STARLIGHT-1 Phase I/II Clinical Study Of EB103 In Patients With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma